1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Otsuka's Guadecitabine Fails in ASTRAL-1 But AML Studies Continue

 
• By John Davis

Otsuka's guadecitabine has missed co-primary endpoints in older treatment-naïve AML patients but it continues to be evaluated in relapsed and refractory patients, in a therapeutic area undergoing considerable innovation.  

SC1808_Roller Coaster Road_350267387_1200.jpg
Drug development can be an up and down journey. • Source: Shutterstock

Astex Pharmaceuticals Inc./Otsuka Holdings Co. Ltd.'s potential next-generation leukemia therapy, guadecitabine, has missed its co-primary endpoints in the Phase III ASTRAL-1 study in older patients with previously untreated acute myeloid leukemia (AML).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.